A carregar...
Population Pharmacokinetic Modeling and Exposure–Response Assessment for the Antibody‐Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON‐1 Study
The efficacy of the CD30‐directed antibody‐drug conjugate (ADC) brentuximab vedotin was established in combination with chemotherapy as frontline treatment for advanced classical Hodgkin's lymphoma in the randomized phase III ECHELON‐1 study. Population pharmacokinetic (PK) and exposure–respons...
Na minha lista:
| Publicado no: | Clin Pharmacol Ther |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6896233/ https://ncbi.nlm.nih.gov/pubmed/31152605 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1530 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|